The firm is aiming to break even on its cash flow by 2027 by narrowing its focus on its sarcoma treatments and pipeline candidates with greatest potential.
The firm aims to advance two breast cancer therapies in HR-positive, HER2-negative advanced breast cancer this year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback